747392-34-3

Basic information

• Product Name: 2-Bromo-5-fluorobenzylamine
• Synonyms: 2-Bromo-5-fluorobenzylamine
• CAS NO: 747392-34-3
• Molecular Formula: C₇H₇BrFN
• Molecular Weight: 204.04
• EINECS: 923-293-5
• Product Categories: Fluorine series
• Mol File: 747392-34-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 235.4 °C at 760 mmHg
• Flash Point: 96.2 °C
• Appearance: /
• Density: 1.571 g/cm³
• Vapor Pressure: 0.0502mmHg at 25°C
• Refractive Index: 1.566
• PKA: 8.26±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-5-fluorobenzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-fluorobenzylamine(747392-34-3)
• EPA Substance Registry System: 2-Bromo-5-fluorobenzylamine(747392-34-3)

Safety Data

• Hazardous Substances Data: 747392-34-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-fluorobenzylamine is a chemical compound with the molecular formula C7H7BrFN, and a molecular weight of 200.04 g/mol. It is a member of the amino benzenes and aniline family of compounds, which are widely used in the pharmaceutical and agrochemical industries. 2-Bromo-5-fluorobenzylamine is a benzylamine derivative, with a bromine atom at the 2-position and a fluorine atom at the 5-position on the benzene ring. It is commonly used as a building block in the synthesis of various pharmaceuticals and biologically active molecules due to its diverse reactivity and ability to participate in various chemical reactions. 2-Bromo-5-fluorobenzylamine is also used as a research chemical in the development of new drugs and in the study of biological systems.

InChI:InChI=1/C7H7BrFN/c8-7-2-1-6(9)3-5(7)4-10/h1-3H,4,10H2

Upstream product

• 94569-84-3 2-bromo-5-fluorobenzaldehyde 
• 57381-39-2 2-bromo-5-fluorobenzonitrile 
• 1198105-01-9 2-(azidomethyl)-1-bromo-4-fluorobenzene 

Downstream Products

• 880104-97-2 4-methyl-benzenesulfinic acid 2-bromo-5-fluoro-benzylamide 
• 629628-16-6 N-(2-Bromo-5-fluorobenzyl)-4,5-dihydrooxazol-2-amine 
• 1169762-19-9 C₂₆H₃₆BrFN₄O₄ 
• 1338930-86-1 tert-butyl 5-(2-bromo-5-fluorobenzyl)-6-{(3R)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-1,3-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidine-7-carboxylate 
• 1338930-83-8 4-tert-butyl 2-ethyl 3-amino-1-(2-bromo-5-fluorobenzyl)-5-{(3R)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-1H-pyrrole-2,4-dicarboxylate 
• 1358684-71-5 tert-butyl (2-bromo-5-fluorobenzyl)carbamate 

Relevant articles and documents

Palladium-Catalyzed α-Arylation of Silylenol Ethers in the Synthesis of Isoquinolines and Phenanthridines

A diverse array of isoquinolines and phenanthridines have been accessed by developing a two-step, one-pot method constituting regioselective palladium-catalyzed Kuwajima-Urabe α-arylation of silylenol ethers and acid-mediated deprotection, annulation, and aromatization. Structural diversity in the silylenol ethers leads to three different classes of isoquinolines and phenanthridines from which related natural products can be derived. The synthetic utility of this method by the quick assembly of the natural product trispheridine is also demonstrated.

Synthesis of a unique isoindoline/tetrahydroisoquinoline-based tricyclic sultam library utilizing a Heck-aza-Michael strategy

The synthesis of a unique isoindoline- and tetrahydroisoquinoline (THIQ)-containing tricyclic sultam library, utilizing a Heck-aza-Michael (HaM) strategy is reported. Both isoindoline and THIQ rings are installed through a Heck reaction on a vinylsulfonamide, followed by one-pot deprotection and intramolecular aza-Michael reaction. Subsequent cyclization with either paraformaldehyde condensation or 1,1′-carbonyldiimidazole coupling generates a variety of tricyclic sultams. Overall, a 160-member library of these sultams, together with their isoindolines/THIQ and secondary sulfonamides precursors, were constructed using this strategy.

NOVEL METHODS AND COMPOSITIONS FOR ALLEVIATING PAIN

The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic α-adrenergic receptor in the absence of α-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic α-adrenergic receptor can be, for example, the α-2B receptor.